AuthorisedTherapeutic exploratory (Phase II)Interventional

Optimizing Lymph Node Staging in Esophageal Cancer with USPIO-enhanced MRI

This research is looking into a new way to find if oesophageal cancer has spread to the lymph nodes. It compares a special type of MRI scan, which uses a tracer called USPIO, with the usual PET-CT scans. Doctors want to see how good the new MRI is at spotting cancer in these nodes, how long it takes doctors to look at the images, and how patients feel about having the scan compared to a PET-CT. The goal is to find out if this USPIO-enhanced MRI could be a more effective or comfortable way for patients to get important information about their cancer.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Amsterdam UMC

Enrolment target

Start

31 Jul 2025

Esophageal cancer

What is this study about?

When someone has oesophageal cancer, it's really important for doctors to know if the cancer has spread to nearby lymph nodes. This information helps them plan the best treatment. Currently, a common way to check for this spread is using a PET-CT scan.

This study is testing a different type of scan, called a USPIO-enhanced MRI. Imagine it like a regular MRI, but with a special 'dye' (called USPIO) given to you beforehand. This dye helps the MRI scanner see the lymph nodes more clearly, especially if there are tiny cancer cells within them. The researchers want to see if this new MRI scan is better at finding these cancer cells compared to the standard PET-CT scan.

The study will look at several things: how good the pictures from the USPIO-enhanced MRI are, how quickly doctors can tell if cancer is present, and what patients think about having this new scan compared to a PET-CT. They'll also carefully compare the accuracy of both scans against the true diagnosis found through other tests. Ultimately, this research aims to find an improved or more comfortable way for people with oesophageal cancer to get the vital information needed for their treatment plan.

Key takeaways

This study compares a new MRI method to standard PET-CT for finding cancer in lymph nodes.
It's for people with oesophageal cancer aged 18 and over.
The new MRI uses a special tracer (USPIO) to improve image clarity.
Researchers will check how accurate and patient-friendly the new MRI is.
You'll share your thoughts on the scan experience through questionnaires.
The aim is to find better ways to provide information for cancer treatment.

Who may be eligible?

This study is looking for both men and women who are 18 years old or older. There is no upper age limit, so older adults can also take part.

To be eligible, you must have oesophageal cancer. The research team will check other specific health details to make sure the study is safe and suitable for you. These checks will include your general health and any other medical conditions you might have.

It's important to discuss with your doctor whether this study is right for your specific situation. They can help you understand all the requirements and decide if you qualify.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am 18 years old or older.
I have been diagnosed with oesophageal cancer.
I am able to have an MRI scan.
I am able to have a PET-CT scan.
I am willing to complete questionnaires about my scan experience.

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you will have a special MRI scan using a substance called USPIO. This involves having a small amount of the USPIO tracer given to you, likely through a drip, before your MRI scan. You will also have standard PET-CT scans, which you might already be scheduled for as part of your usual care, or they might be arranged for the study.

Throughout the study, doctors will carefully assess the images from both scans. You will also be asked to fill out a questionnaire to share your thoughts and feelings about your experience with both types of scans. This helps researchers understand which scan is easier or more comfortable for patients. The study will also involve monitoring for any side effects from the USPIO tracer. The total duration of your participation will depend on the various appointments and follow-ups needed for both the new MRI and standard procedures, which will be explained in detail.

Potential risks and benefits

Taking part in this study might offer you the chance to have advanced scans that could give more detailed information about your cancer, potentially helping doctors plan your treatment more effectively. While the USPIO tracer used in the MRI is generally safe, there's a small chance of side effects, like any medicine. These will be carefully monitored by the study team. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands

Common questions

What is oesophageal cancer?

Oesophageal cancer is a type of cancer that develops in the food pipe, which is the tube that connects your throat to your stomach.

What are lymph nodes?

Lymph nodes are small, bean-shaped glands found throughout your body. They are part of your immune system and help filter out harmful substances and fight infections. Cancer can sometimes spread to these nodes.

What is a PET-CT scan?

A PET-CT scan is a common imaging test that combines two types of scans (PET and CT) to create detailed pictures of the inside of your body, often used to find cancer.

What is USPIO-enhanced MRI?

This is a special type of MRI scan where a substance called USPIO is used to make lymph nodes show up more clearly on the images, helping doctors to spot if cancer has spread to them.

Will I receive treatment as part of this study?

This study is focused on improving how we diagnose cancer spread, not on providing treatment for your cancer itself. Your treatment will continue to be planned by your doctors based on your diagnosis.